
As I come to the end of my term at ENDO 2025 next month in San Francisco, Calif., I can look back with great pride at what the Endocrine Society has accomplished over the past 12 months.
My experience as your president also has reaffirmed my belief that belonging to a strong community is crucial to achieving one’s goals, both individually and collectively. Here at the Society, we’re fortunate to belong to such an engaged and compassionate community of endocrine clinicians and researchers, hailing from every corner of the globe. Moreover, now, more than any recent period that comes to mind, we need to stand firm together and by so doing ensure the future of our discipline and care for patients.
Together with our dedicated staff, members of the Society have advanced many important initiatives over the past 12 months, including the addition of new meetings, new guidelines, and new member programs.
I want to highlight just some of these accomplishments, while also pointing out challenges where more work is needed, work that will continue at the Society.
Helping Guide Clinical Practice
One of the Society’s most important contributions to public health is providing guidance on best practices to improve care for patients.
In March 2025, we gathered wide-ranging public comments on two upcoming clinical practice guidelines (CPGs), that are then used to refine the final versions that are scheduled for publication this summer. The guidelines, which update previous guidelines, are: (1) The Management of Primary Aldosteronism: an update to a 2016 guideline, and (2) Diabetes in Pregnancy: an update done jointly with the European Society of Endocrinology of a 2013 guideline developed by the Society.
I really recommend that you explore all of our 33 CPGs across 12 practice areas.
Meetings & Continuing Education
Our multifaceted community also has been busy creating meetings that meet the needs of our diverse membership. Last autumn member volunteers working with staff launched two new meetings.
In November 2024, we held our inaugural Artificial Intelligence (AI) in Healthcare Virtual Summit, which explored AI’s potential to revolutionize patient care and shape the future of medicine. And in October 2024, we held our 1st International Conference on Steroid Hormones and Receptors (SHR 2024) in Albuquerque, N.M. The sold-out event continued a 25-year run of conferences organized by The Steroid Hormones and Receptors in Health and Disease Conference.
These came on top of our regular slate of outstanding meetings. In September 2025, we held Endocrine Board Review (EBR) and Clinical Endocrinology Update (CEU), both virtual meetings.
And in July 2025, we will hold what undoubtedly will be a highly successful ENDO 2025 in San Francisco, Calif. We’re anticipating another blockbuster meeting, with more than 200 educational sessions, more than 2,800 abstracts, and more than 7,000 endocrine professionals attending from all over the world.
Strengthening Members and the Organization
In addition to meetings, the Society community also focuses on helping members connect and advance in their careers through ongoing programming.
Nowhere is this more evident than in our growing number of Special Interest Groups (SIGs), which have become popular venues for members to discuss research and clinical cases, as well as network.
My experience as your president also has reaffirmed my belief that belonging to a strong community is crucial to achieving one’s goals, both individually and collectively. Here at the Society, we’re fortunate to belong to such an engaged and compassionate community of endocrine clinicians and researchers, hailing from every corner of the globe. Moreover, now, more than any recent period that comes to mind, we need to stand firm together and by so doing ensure the future of our discipline and care for patients.
Last year, we added two new SIGs, one focused on obesity and another on neuroendocrinology, bringing the total number of SIGs up to ten. To best serve these groups, we launched a SIG Newsletter, called SIGs Wrap-Up!, which highlights upcoming events, lists new research in the SIG topic areas, points out interesting discussions in the SIG communities, and provides announcements from SIG leaders, among other things.
We also saw a surge in the number of medical schools selected for the second year of our Medical School Engagement Program (MSEP). The 11 recipients, announced in May 2025, stood out with exceptional leadership in education, innovative approaches, and unwavering commitment to advancing the field of endocrinology by increasing medical students’ exposure to all the exciting aspects of this specialty. They join the 10 schools that were selected during MSEP’s inaugural last year. View the 2025 awardees.
Advocacy Efforts in Challenging Times
Our advocacy team has been working diligently to oppose government funding cutbacks to U.S. clinical and medical research programs.
In April 2025, we expressed our disappointment with the administration’s decision not to finalize a rule that would have extended coverage of anti-obesity medications under Medicare and Medicaid. The Society will continue to advocate for policies to make anti-obesity medications more accessible.
Similarly, in March 2025, we warned that massive cuts to the U.S. Department of Health and Human Services (HHS) threatens scientific progress that drives the economy and improves public health.
Also in March 2025, we called on the administration to restore the Diabetes Prevention Program (DPP), a three decade-long research project into type 2 diabetes prevention. Funded through the NIH, the landmark program and its companion DPP Outcomes Study were abruptly ended due to government funding cuts.
Finally, last year, the Society took steps to strengthen the organization itself.
In July 2024, we announced a merger with the Association of Program Directors in Endocrinology, Diabetes and Metabolism (APDEM), which represents academic leaders of more than 135 training programs that prepare fellows for clinical and research careers in endocrinology and metabolism.
These events, programs and activities only scratch the surface of what’s going on at the Endocrine Society, and under the leadership of my successor Carol Lange, the Society will continue the great work that is always evident in our community.
It has been an honor to serve as the Society’s first non-U.S.-based president. I want to thank you and all the staff for being part of this marvelous community, and I look forward to seeing you at ENDO 2025 in San Francisco.